Treatment of peritoneal metastases from small bowel adenocarcinoma

References

• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
   PubMed Web of Science ®Google Scholar
• Howe JR, Karnell LH, Menck HR, et al. (1999). Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985–1995. Cancer 86:2693–706.
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Goetz LH, Rao S, Joehl RJ. (2002). Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 137:564–70.
   PubMed Web of Science ®Google Scholar
• Lepage C, Bouvier AM, Manfredi S, et al. (2006). Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 101:2826–32.
   PubMed Web of Science ®Google Scholar
• Hatzaras I, Palesty JA, Abir F, et al. (2007). Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut tumor registry. Arch Surg 142:229–35.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Wayne JD, et al. (2009). Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 249:63–71.
   PubMed Web of Science ®Google Scholar
• Legué LM, Bernards N, Gerritse SL, et al. (2016). Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in the Netherlands. Acta Oncol 55:1183–9.
   PubMed Web of Science ®Google Scholar
• Debaja BS, Suki D, Pro B, et al. (2004). Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101:518–26.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. (2010). A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 199:797–803.
   PubMed Web of Science ®Google Scholar
• Locher C, Malka D, Boige V, et al. (2005). Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 69:290–4.
   PubMed Web of Science ®Google Scholar
• Fishman PN, Pond GR, Moore MJ, et al. (2006). Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 29:225–31.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Kopetz S, Wen S, et al. (2008). Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113:2038–45.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Varadhachary GR, Kopetz S, et al. (2009). Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 27:2598–603.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Costes L, Gauthier M, et al. (2010). Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 21:1786–93.
   PubMed Web of Science ®Google Scholar
• Zaanan A, Gauthier M, Malka D, et al. (2011). Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 117:1422–8.
   PubMed Web of Science ®Google Scholar
• Koo DH, Yun SC, Hong YS, et al. (2011). Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer 11:205.
   PubMed Web of Science ®Google Scholar
• Tsushima T, Taguri M, Honma Y, et al. (2012). Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 17:1163–70.
   PubMed Web of Science ®Google Scholar
• Xiang XJ, Liu YW, Zhang L, et al. (2012). A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 23:561–6.
   PubMed Web of Science ®Google Scholar
• Crawley C, Ross P, Norman A, et al. (1998). The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 78:508–10.
   PubMed Web of Science ®Google Scholar
• Polyzos A, Kouraklis G, Giannopoulos A, et al. (2003). Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother 15:503–6.
   PubMed Web of Science ®Google Scholar
• Gibson MK, Holcroft CA, Kvols LK, Haller D. (2005). Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 10:132–7.
   PubMed Web of Science ®Google Scholar
• Czaykowski P, Hui D. (2007). Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columba Cancer Agency. Clin Oncol (R Coll Radiol) 19:143–9.
   PubMed Web of Science ®Google Scholar
• Ono M, Shirao K, Takashima A, et al. (2009). Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer 11:201–5.
   Web of Science ®Google Scholar
• Suenaga M, Mizunuma N, Chin K, et al. (2009). Chemotherapy for small-bowel adenocarcinoma at a single institution. Surg Today 39:27–31.
   PubMed Web of Science ®Google Scholar
• Moon YW, Rha SY, Shin SJ, (2010). Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol 136:387–94.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang LY, Deng YM, et al. (2011). Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J Buon 16:689–96.
   PubMed Web of Science ®Google Scholar
• Khan K, Peckitt C, Sclafani F, et al. (2015). Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer 15:15.
   PubMed Web of Science ®Google Scholar
• Assersohn L, Norman A, Cunningham D, et al. (1999). Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 79:1800–5.
   PubMed Web of Science ®Google Scholar
• Kohne CH, Cunningham D, di Constanzo F, et al. (2002). Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastastic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13:308–17.
   PubMed Web of Science ®Google Scholar
• Franko J, Shi Q, Goldman CD, et al. (2012). Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 30:263–7.
   PubMed Web of Science ®Google Scholar
• Klaver YL, Simkens LH, Lemmens VE, et al. (2012). Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol 38:617–23.
   PubMed Web of Science ®Google Scholar
• Franko J, Shi Q, Meyers JP, et al. (2016). Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 17:1709–19.
   PubMed Web of Science ®Google Scholar
• Elias D, Goéré D, Dumont F, et al. (2014). Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50:332–40.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Pietrantonio F, et al. (2016). Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 100:209–22.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Svrcek M, Zaanan A, et al. (2013). Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 109:3057–66.
   PubMed Web of Science ®Google Scholar
• Zaaimi Y, Aparicio T, Laurent-Puig P, et al. (2016). Advanced small bowel adenocarcinoma: molecular characteristics and therapeutic perspectives. Clin Res Hepatol Gastroenterol 40:154–60.
   PubMed Web of Science ®Google Scholar
• Marchettini P, Sugarbaker PH. (2002). Mucinous adenocarcinoma of the small bowel with peritoneal seeding. Eur J Surg Oncol 28:19–23.
   PubMed Web of Science ®Google Scholar
• Jacks SP, Hundley JC, Shen P, et al. (2005) Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol 91:112–17.
   PubMed Web of Science ®Google Scholar
• Chua TC, Koh JL, Yan TD, et al. (2009). Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol 100:139–43.
   PubMed Web of Science ®Google Scholar
• Elias D, Glehen O, Pocard M, et al. (2010). A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 251:896–901.
   PubMed Web of Science ®Google Scholar
• Sun Y, Shen P, Stewart JH, et al. (2013). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Am Surg 79:644–8.
   PubMed Web of Science ®Google Scholar
• van Oudheusden TR, Lemmens VE, Braam HJ, et al. (2015). Peritoneal metastases from small bowel cancer: results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the Netherlands Surgery 157:1023–7.
   Google Scholar
• Liu Y, Ishibashi H, Takeshita K, et al. (2016). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from small bowel malignancy: results from a single specialized center. Ann Surg Oncol 23:1625–31.
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. (1981). Reporting results of cancer treatment. Cancer 47:207–14.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–16.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–47.
   PubMed Web of Science ®Google Scholar
• Trotti A, Byhardt R, Stetz J, et al. (2000). Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–81.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien PA. (2004). Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–13.
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J, et al. (2007). Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370:135–42.
   PubMed Web of Science ®Google Scholar
• Lee DH, Oh SY, Lee YR, et al. (2011). A phase II study of modified FOLFOX4 for colorectal cancer patients with peritoneal carcinomatosis. Cancer Res Treat 43:225–30.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. (2013). Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18:1004–12.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Pozadzides J, Kopetz S, et al. (2010). Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102:144–50.
   PubMed Web of Science ®Google Scholar
• Razenberg LG, van Gestel YR, Lemmens VE, et al. (2016). Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study. Clin Colorectal Cancer 15:e41–6.
   PubMed Web of Science ®Google Scholar
• Tamsma JT, Keizer HJ, Meinders AE. (2001). Pathogenesis of malignant ascites: Starling’s law of capillary hemodynamics revisited. Ann Oncol 12:1353–7.
   PubMed Web of Science ®Google Scholar
• Esquivel J, Piso P, Verwaal V, et al. (2014). American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol 110:777–8.
   PubMed Web of Science ®Google Scholar
• Lam JY, McConnell YJ, Rivard JD, et al. (2015). Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg 210:424–30.
   PubMed Web of Science ®Google Scholar
• Elias D, Benizri E, di Pietrantonio D, et al. (2007). Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 14:509–14.
   PubMed Web of Science ®Google Scholar
• McConnell YJ, Mack L, Francis WP, et al. (2013). HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 107:591–6.
   PubMed Web of Science ®Google Scholar
• Tan GH, Ong WS, Chia CS, et al. (2016). Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?. Int J Hyperthermia 32:281–8.
   PubMed Web of Science ®Google Scholar
• Maillet M, Glehen O, Lambert J, et al. (2016). Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol 23:863–9.
   PubMed Web of Science ®Google Scholar
• Devilee RA, Simkens GA, van Oudheusden TR, et al. (2016). Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 23:2841–8.
   PubMed Web of Science ®Google Scholar
• Ceelen W, van Nieuwenhove Y, Putte DV, Pattyn P. (2014). Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol 21:3023–8.
   PubMed Web of Science ®Google Scholar
• Eveno C, Passot G, Goéré D, et al. (2014). Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 21:1792–800.
   PubMed Web of Science ®Google Scholar
• Cavaliere F, de Simone M, Virzi S, et al. (2011). Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 37:148–54.
   PubMed Web of Science ®Google Scholar
• Solass W, Kerb R, Mürdter T, et al. (2014). Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553–9.
   PubMed Web of Science ®Google Scholar
• Nadiradze G, Giger-Pabst U, Zieren J, et al. (2016). Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastases. J Gastrointest Surg 20:367–73.
   PubMed Web of Science ®Google Scholar
• Demtröder C, Solass W, Zieren J, et al. (2016). Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Coloretal Dis 18:364–71.
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Rezniczek GA, Ende P, et al. (2015). Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study. Anticancer Res 35:6723–9.
   PubMed Web of Science ®Google Scholar
• Odendahl K, Solass W, Demtröder C, et al. (2015). Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol 41:1379–85.
   PubMed Web of Science ®Google Scholar